Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 275

1.

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.

Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F.

Lancet Haematol. 2019 Jan;6(1):e29-e37. doi: 10.1016/S2352-3026(18)30182-0. Epub 2018 Dec 10.

PMID:
30545576
2.

Passive, continuous monitoring of carbon dioxide geostorage using muon tomography.

Gluyas J, Thompson L, Allen D, Benton C, Chadwick P, Clark S, Klinger J, Kudryavtsev V, Lincoln D, Maunder B, Mitchell C, Nolan S, Paling S, Spooner N, Staykov L, Telfer S, Woodward D, Coleman M.

Philos Trans A Math Phys Eng Sci. 2018 Dec 10;377(2137). pii: 20180059. doi: 10.1098/rsta.2018.0059.

3.

Implementing Clinical Pharmacogenomics in the Classroom: Student Pharmacist Impressions of an Educational Intervention Including Personal Genotyping.

Frick A, Benton C, Suzuki O, Dong O, Howard R, El-Sabae H, Wiltshire T.

Pharmacy (Basel). 2018 Oct 23;6(4). pii: E115. doi: 10.3390/pharmacy6040115.

4.

Early detection of transformation to BPDCN in a patient with MDS.

Chamoun K, Loghavi S, Pemmaraju N, Konopleva M, Kroll M, Nguyen-Cao M, Hornbaker M, DiNardo CD, Kadia T, Jorgensen J, Andreeff M, Hu S, Benton CB.

Exp Hematol Oncol. 2018 Oct 6;7:26. doi: 10.1186/s40164-018-0117-6. eCollection 2018.

5.

Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.

Benton CB, Chien KS, Tefferi A, Rodriguez J, Ravandi F, Daver N, Jabbour E, Jain N, Alvarado Y, Kwari M, Pierce S, Maiti A, Hornbaker M, Santos MA, Martinez S, Siguero M, Zblewski D, Al-Kali A, Hogan WJ, Kantarjian H, Pardanani A, Garcia-Manero G.

Hematol Oncol. 2019 Feb;37(1):96-102. doi: 10.1002/hon.2557. Epub 2018 Dec 5.

PMID:
30153704
6.

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.

Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H.

Lancet Haematol. 2018 Sep;5(9):e411-e421. doi: 10.1016/S2352-3026(18)30132-7. Epub 2018 Aug 13.

PMID:
30115541
7.

Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R.

Benton CB, Khan M, Sallman D, Nazha A, Nogueras González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, Kadia TM, Borthakur G, Ravandi F, Pierce S, Steensma D, DeZern A, Roboz G, Sekeres M, Andreeff M, Kantarjian H, Komrokji RS, Garcia-Manero G.

Am J Hematol. 2018 Oct;93(10):1245-1253. doi: 10.1002/ajh.25234. Epub 2018 Sep 26.

PMID:
30051599
8.

Inbreeding intensifies sex- and age-dependent disease in a wild mammal.

Benton CH, Delahay RJ, Smith FAP, Robertson A, McDonald RA, Young AJ, Burke TA, Hodgson D.

J Anim Ecol. 2018 Nov;87(6):1500-1511. doi: 10.1111/1365-2656.12878. Epub 2018 Jul 20.

PMID:
29938787
9.

Representation of facial identity includes expression variability.

Redfern AS, Benton CP.

Vision Res. 2018 May 23. pii: S0042-6989(18)30080-4. doi: 10.1016/j.visres.2018.05.004. [Epub ahead of print]

10.

Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels.

DiNardo CD, Routbort MJ, Bannon SA, Benton CB, Takahashi K, Kornblau SM, Luthra R, Kanagal-Shamanna R, Medeiros LJ, Garcia-Manero G, M Kantarjian H, Futreal PA, Meric-Bernstam F, Patel KP.

Cancer. 2018 Jul 1;124(13):2704-2713. doi: 10.1002/cncr.31331. Epub 2018 Apr 6. Review.

PMID:
29682723
11.

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.

Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour EJ, Benton CB, DiNardo CD, Konopleva M, Daver N, Patel K, Takahashi K, Kanagal-Shamanna R, Cortes J, Kadia T.

Leuk Lymphoma. 2018 Sep;59(9):2238-2241. doi: 10.1080/10428194.2017.1422864. Epub 2018 Jan 17. No abstract available.

PMID:
29338567
12.

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.

Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM.

Blood Adv. 2017 Jul 19;1(17):1312-1323. doi: 10.1182/bloodadvances.2017008227. eCollection 2017 Jul 25.

13.

Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.

DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M.

Am J Hematol. 2018 Mar;93(3):401-407. doi: 10.1002/ajh.25000. Epub 2017 Dec 23.

PMID:
29218851
14.

A mind map for managing minimal residual disease in acute myeloid leukemia.

Benton CB, Ravandi F.

Clin Adv Hematol Oncol. 2017 Nov;15(11):859-867. Review.

PMID:
29200419
15.

JAK2V617F detection and allele burden measurement in saliva vs. peripheral blood in patients with myelofibrosis.

Strati P, Benton CB, Manshouri T, Zhang Y, Bove JE 4th, Sanchez-Petitto G, Verstovsek S.

Leuk Res. 2017 Dec;63:53-55. doi: 10.1016/j.leukres.2017.10.016. Epub 2017 Oct 31.

PMID:
29101828
16.

Expressive Faces Confuse Identity.

Redfern AS, Benton CP.

Iperception. 2017 Sep 19;8(5):2041669517731115. doi: 10.1177/2041669517731115. eCollection 2017 Sep-Oct.

17.

Erythroleukemia-historical perspectives and recent advances in diagnosis and management.

Boddu P, Benton CB, Wang W, Borthakur G, Khoury JD, Pemmaraju N.

Blood Rev. 2018 Mar;32(2):96-105. doi: 10.1016/j.blre.2017.09.002. Epub 2017 Sep 18. Review.

PMID:
28965757
18.

Targeting Histone Acetylation: Readers and Writers in Leukemia and Cancer.

Benton CB, Fiskus W, Bhalla KN.

Cancer J. 2017 Sep/Oct;23(5):286-291. doi: 10.1097/PPO.0000000000000284. Review.

PMID:
28926429
19.

Influence of IDH on FLT3-ITD status in newly diagnosed AML.

Boddu P, Takahashi K, Pemmaraju N, Daver N, Benton CB, Pierce S, Konopleva M, Ravandi F, Cortes J, Kantarjian H, DiNardo CD.

Leukemia. 2017 Nov;31(11):2526-2529. doi: 10.1038/leu.2017.244. Epub 2017 Jul 28. No abstract available.

PMID:
28751773
20.

A directly comparative two-gate case-control diagnostic accuracy study of the pure tone screen and HearCheck screener tests for identifying hearing impairment in school children.

Ukoumunne OC, Hyde C, Ozolins M, Zhelev Z, Errington S, Taylor RS, Benton C, Moody J, Cocking L, Watson J, Fortnum H.

BMJ Open. 2017 Jul 11;7(7):e017258. doi: 10.1136/bmjopen-2017-017258.

21.

Hearing aids for otitis media with effusion: Do children use them?

Gan RWC, Overton P, Benton C, Daniel M.

Int J Pediatr Otorhinolaryngol. 2017 Aug;99:117-119. doi: 10.1016/j.ijporl.2017.05.027. Epub 2017 Jun 14.

PMID:
28688552
22.

Expression Dependence in the Perception of Facial Identity.

Redfern AS, Benton CP.

Iperception. 2017 Jun 1;8(3):2041669517710663. doi: 10.1177/2041669517710663. eCollection 2017 May-Jun.

23.

Ultra-fast LC-MS/MS in therapeutic drug monitoring: Quantification of clozapine and norclozapine in human plasma.

Couchman L, Fisher DS, Subramaniam K, Handley SA, Boughtflower RJ, Benton CM, Flanagan RJ.

Drug Test Anal. 2018 Feb;10(2):323-329. doi: 10.1002/dta.2223. Epub 2017 Jul 19.

PMID:
28585411
24.

Perceived duration of brief visual events is mediated by timing mechanisms at the global stages of visual processing.

Beattie L, Curran W, Benton CP, Harris JM, Hibbard PB.

R Soc Open Sci. 2017 Mar 1;4(3):160928. doi: 10.1098/rsos.160928. eCollection 2017 Mar.

25.

Increased peripheral leukemia blasts leading to false-positive blood culture.

Khan M, Siddiqi R, Konopleva M, Bhatti MM, Benton CB.

Blood Cells Mol Dis. 2017 May;64:8-9. doi: 10.1016/j.bcmd.2017.02.005. Epub 2017 Feb 28. No abstract available.

PMID:
28285097
26.

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M.

Blood. 2017 May 4;129(18):2584-2587. doi: 10.1182/blood-2016-11-749903. Epub 2017 Feb 28. No abstract available.

27.

Aftereffects support opponent coding of expression.

Rhodes G, Pond S, Jeffery L, Benton CP, Skinner AL, Burton N.

J Exp Psychol Hum Percept Perform. 2017 Mar;43(3):619-628. doi: 10.1037/xhp0000322.

PMID:
28240931
28.

FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B-cell acute leukemia.

Ishizawa J, Sugihara E, Kuninaka S, Mogushi K, Kojima K, Benton CB, Zhao R, Chachad D, Hashimoto N, Jacamo RO, Qiu Y, Yoo SY, Okamoto S, Andreeff M, Kornblau SM, Saya H.

Blood. 2017 Apr 6;129(14):1958-1968. doi: 10.1182/blood-2016-07-726216. Epub 2017 Jan 31.

29.

Perceived Duration Increases with Contrast, but Only a Little.

Benton CP, Redfern AS.

Front Psychol. 2016 Dec 15;7:1950. doi: 10.3389/fpsyg.2016.01950. eCollection 2016.

30.

Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.

Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E.

Am J Hematol. 2017 Mar;92(3):238-243. doi: 10.1002/ajh.24625. Epub 2017 Feb 3.

31.

Changes in urinary metabolomic profile during relapsing renal vasculitis.

Al-Ani B, Fitzpatrick M, Al-Nuaimi H, Coughlan AM, Hickey FB, Pusey CD, Savage C, Benton CM, O'Brien EC, O'Toole D, Mok KH, Young SP, Little MA.

Sci Rep. 2016 Dec 1;6:38074. doi: 10.1038/srep38074.

32.

Targeting acute myeloid leukemia with TP53-independent vosaroxin.

Benton CB, Ravandi F.

Future Oncol. 2017 Jan;13(2):125-133. Epub 2016 Sep 12. Review.

33.

Transitioning Pharmacogenomics into the Clinical Setting: Training Future Pharmacists.

Frick A, Benton CS, Scolaro KL, McLaughlin JE, Bradley CL, Suzuki OT, Wang N, Wiltshire T.

Front Pharmacol. 2016 Aug 8;7:241. doi: 10.3389/fphar.2016.00241. eCollection 2016.

34.

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy.

Short NJ, Benton CB, Chen HC, Qiu P, Gu L, Pierce S, Brandt M, Maiti A, Min TL, Naqvi K, Quintas-Cardama A, Konopleva M, Kadia T, Cortes J, Garcia-Manero G, Ravandi F, Jabbour E, Kantarjian H, Andreeff M.

Am J Hematol. 2016 Dec;91(12):1221-1226. doi: 10.1002/ajh.24500. Epub 2016 Aug 29.

35.

Blood thicker than water: kinship, disease prevalence and group size drive divergent patterns of infection risk in a social mammal.

Benton CH, Delahay RJ, Robertson A, McDonald RA, Wilson AJ, Burke TA, Hodgson D.

Proc Biol Sci. 2016 Jul 27;283(1835). pii: 20160798. doi: 10.1098/rspb.2016.0798.

36.

Mixed angioinvasive exserohilum and scedosporium infection in a patient with AML.

Jain P, Nagarajan P, Prayag P, Benton CB, Kadia T, Groisberg R, Kontoyiannis DP, Mulanovich VE, Pemmaraju N.

Am J Hematol. 2017 Jan;92(1):119-120. doi: 10.1002/ajh.24455. Epub 2016 Jul 14. No abstract available.

37.

Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes.

Tamamyan GN, Kantarjian HM, Ning J, Jain P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F, Konopleva MY, Garcia-Manero G, Benton CB, Chihara D, Rytting ME, Wang S, Abdelall W, Konoplev SN, Daver NG.

Cancer. 2016 Sep 15;122(18):2857-66. doi: 10.1002/cncr.30084. Epub 2016 May 31.

38.

Incorporation of poison center services in a state-wide overdose education and naloxone distribution program.

Doyon S, Benton C, Anderson BA, Baier M, Haas E, Hadley L, Maehr J, Rebbert-Franklin K, Olsen Y, Welsh C.

Am J Addict. 2016 Jun;25(4):301-6. doi: 10.1111/ajad.12384. Epub 2016 May 24.

PMID:
27219823
39.

A programme of studies including assessment of diagnostic accuracy of school hearing screening tests and a cost-effectiveness model of school entry hearing screening programmes.

Fortnum H, Ukoumunne OC, Hyde C, Taylor RS, Ozolins M, Errington S, Zhelev Z, Pritchard C, Benton C, Moody J, Cocking L, Watson J, Roberts S.

Health Technol Assess. 2016 May;20(36):1-178. doi: 10.3310/hta20360.

40.

Adapting to time: Duration channels do not mediate human time perception.

Curran W, Benton CP, Harris JM, Hibbard PB, Beattie L.

J Vis. 2016;16(5):4. doi: 10.1167/16.5.4.

PMID:
26943349
41.

Biological movement and the encoding of its motion and orientation.

Benton CP, Thirkettle M, Scott-Samuel NE.

Sci Rep. 2016 Feb 29;6:22393. doi: 10.1038/srep22393.

42.

Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.

Ruvolo PP, Ruvolo VR, Benton CB, AlRawi A, Burks JK, Schober W, Rolke J, Tidmarsh G, Hail N Jr, Davis RE, Andreeff M.

Biochim Biophys Acta. 2016 Apr;1863(4):562-71. doi: 10.1016/j.bbamcr.2015.12.008. Epub 2015 Dec 17.

43.

Disparities in road crash mortality among pedestrians using wheelchairs in the USA: results of a capture-recapture analysis.

Kraemer JD, Benton CS.

BMJ Open. 2015 Nov 20;5(11):e008396. doi: 10.1136/bmjopen-2015-008396.

44.

Identifying genes that mediate anthracyline toxicity in immune cells.

Frick A, Suzuki OT, Benton C, Parks B, Fedoriw Y, Richards KL, Thomas RS, Wiltshire T.

Front Pharmacol. 2015 Apr 15;6:62. doi: 10.3389/fphar.2015.00062. eCollection 2015.

45.

Immune cell-based screening assay for response to anticancer agents: applications in pharmacogenomics.

Frick A, Fedoriw Y, Richards K, Damania B, Parks B, Suzuki O, Benton CS, Chan E, Thomas RS, Wiltshire T.

Pharmgenomics Pers Med. 2015 Feb 26;8:81-98. doi: 10.2147/PGPM.S73312. eCollection 2015.

46.

Chronic myelomonocytic leukemia: Forefront of the field in 2015.

Benton CB, Nazha A, Pemmaraju N, Garcia-Manero G.

Crit Rev Oncol Hematol. 2015 Aug;95(2):222-42. doi: 10.1016/j.critrevonc.2015.03.002. Epub 2015 Mar 14. Review.

47.

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation.

Konopleva M, Benton CB, Thall PF, Zeng Z, Shpall E, Ciurea S, Kebriaei P, Alousi A, Popat U, Anderlini P, Nieto Y, Parmar S, Qiao W, Chen J, Rondon G, McMullin B, Wang RY, Lu H, Schober W, Woodworth G, Gulbis A, Cool R, Andreeff M, Champlin R.

Bone Marrow Transplant. 2015 Jul;50(7):939-946. doi: 10.1038/bmt.2015.58. Epub 2015 Apr 13.

48.

Deciding on race: a diffusion model analysis of race-categorisation.

Benton CP, Skinner AL.

Cognition. 2015 Jun;139:18-27. doi: 10.1016/j.cognition.2015.02.011. Epub 2015 Mar 19.

49.

Slow change deafness.

Neuhoff JG, Wayand J, Ndiaye MC, Berkow AB, Bertacchi BR, Benton CA.

Atten Percept Psychophys. 2015 May;77(4):1189-99. doi: 10.3758/s13414-015-0871-z.

PMID:
25788038
50.

Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities.

Benton CB, Tanaka M, Wilson C, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S.

Leuk Res. 2015 Apr;39(4):419-23. doi: 10.1016/j.leukres.2015.01.012. Epub 2015 Feb 2.

Supplemental Content

Loading ...
Support Center